PAVmed Inc (PAVM) Jumps 16.5%
On an overall negative day for the PRISM Stock Indexes, PAVmed stood out with a very positive day. PAVM jumped 16.5%, ending with a share price of $1.27 and a daily high of around $1.40.
PAVM is located in the MedDevices and MedDiagnostics indexes, which finished -1.2% and -0.2%, respectively.
PAVM announced yesterday, that the Company will hold a Business Update Conference Call on May 12, 2022.
About PAVmed
PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its major subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD), markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to prevent esophageal cancer deaths. Another major subsidiary, Veris Health Inc., is a digital health company developing the first intelligent implantable vascular access port with biologic sensors and wireless communication to improve personalized cancer care through remote patient monitoring. PAVmed’s CarpX® Minimally Invasive Device for Carpal Tunnel Syndrome is currently in limited commercial release. The product pipeline also includes the EsoCure™ Esophageal Ablation Device with Caldus™ Technology, which complements EsoGuard and EsoCheck, the NextFlo™ Intravenous Infusion Set, the PortIO™ Implantable Intraosseous Vascular Access Device, novel pediatric ear tubes, mechanical circulatory support technology, and glucose monitoring. For more information, please visit www.pavmed.com.
